The western blot and immunofluorescence assay confirmed that LINC-PINT suppressed the expression of the proteins related to Wnt/β-catenin pathway including the key effector β-catenin, the nuclear transcription factor TCF1/TCF7, and the downstream targets C-Jun and CD44, proving that LINC-PINT inhibited Wnt/β-catenin signaling in GBM. The gene discussed is CD44; the disease is glioblastoma.